Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts

Fei Wang, Rhonda K. Hansen, Derek C Radisky, Toshiyuki Yoneda, Mary Helen Barcellos-Hoff, Ole W. Petersen, Eva A. Turley, Mina J. Bissell

Research output: Contribution to journalArticle

206 Citations (Scopus)

Abstract

Background: We previously used a three-dimensional (3D) reconstituted basement membrane (rBM) assay to demonstrate that tumorigenic HMT-3522 T4-2 human breast cells can be induced to form morphologically normal structures ("reversion") by treatment with inhibitors of β1 integrin, the epidermal growth factor receptor (EGFR), or mitogen-activated protein kinase (MAPK). We have now used this assay to identify reversion and/or death requirements of several more aggressive human breast cancer cell lines. Methods: Breast tumor cell lines MCF7, Hs578T, and MDA-MB-231 were cultured in 3D rBM and treated with inhibitors of β1 integrin, MAPK, or phosphatidylinositol 3-kinase (P13K). MDA-MB-231 cells, which lack E-cadherin, were transfected with an E-cadherin cDNA. The extent of reversion was assessed by changes in morphology and polarity, growth in 3D rBM or soft agar, level of invasiveness, and tumor formation in nude mice. Results: All three cell lines showed partial reversion (MCF7 greatest and Hs578T the least) of tumorigenic properties treated with a single β1 integrin, MAPK, or P13K inhibitor. Combined inhibition of β1 integrin and either P13K or MAPK resulted in nearly complete phenotypic reversion (MDA-MB-231, MCF7) or in cell death (Hs578T). E-cadherin-transfected MDA-MB-231 cells showed partial reversion, but exposure of the transfectants to an inhibitor of β1 integrin, P13K, or MAPK led to nearly complete reversion. Conclusion: The 3D rBM assay can be used to identify signaling pathways that, when manipulated in concert, can lead to the restoration of morphologically normal breast structures or to death of the tumor cells, even highly metastatic cells. This approach may be useful to design therapeutic intervention strategies for aggressive breast cancers.

Original languageEnglish (US)
Pages (from-to)1494-1503
Number of pages10
JournalJournal of the National Cancer Institute
Volume94
Issue number19
StatePublished - Oct 2 2002
Externally publishedYes

Fingerprint

Mitogen-Activated Protein Kinases
Integrins
Cell Death
Basement Membrane
Cadherins
Neoplasms
Breast Neoplasms
Breast
Phosphatidylinositol 3-Kinase
Cell Line
Tumor Cell Line
Epidermal Growth Factor Receptor
Nude Mice
Agar
Complementary DNA
Growth
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wang, F., Hansen, R. K., Radisky, D. C., Yoneda, T., Barcellos-Hoff, M. H., Petersen, O. W., ... Bissell, M. J. (2002). Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. Journal of the National Cancer Institute, 94(19), 1494-1503.

Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. / Wang, Fei; Hansen, Rhonda K.; Radisky, Derek C; Yoneda, Toshiyuki; Barcellos-Hoff, Mary Helen; Petersen, Ole W.; Turley, Eva A.; Bissell, Mina J.

In: Journal of the National Cancer Institute, Vol. 94, No. 19, 02.10.2002, p. 1494-1503.

Research output: Contribution to journalArticle

Wang, F, Hansen, RK, Radisky, DC, Yoneda, T, Barcellos-Hoff, MH, Petersen, OW, Turley, EA & Bissell, MJ 2002, 'Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts', Journal of the National Cancer Institute, vol. 94, no. 19, pp. 1494-1503.
Wang, Fei ; Hansen, Rhonda K. ; Radisky, Derek C ; Yoneda, Toshiyuki ; Barcellos-Hoff, Mary Helen ; Petersen, Ole W. ; Turley, Eva A. ; Bissell, Mina J. / Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. In: Journal of the National Cancer Institute. 2002 ; Vol. 94, No. 19. pp. 1494-1503.
@article{c1af6d82b1bd483ea210b16f8a1ae1ec,
title = "Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts",
abstract = "Background: We previously used a three-dimensional (3D) reconstituted basement membrane (rBM) assay to demonstrate that tumorigenic HMT-3522 T4-2 human breast cells can be induced to form morphologically normal structures ({"}reversion{"}) by treatment with inhibitors of β1 integrin, the epidermal growth factor receptor (EGFR), or mitogen-activated protein kinase (MAPK). We have now used this assay to identify reversion and/or death requirements of several more aggressive human breast cancer cell lines. Methods: Breast tumor cell lines MCF7, Hs578T, and MDA-MB-231 were cultured in 3D rBM and treated with inhibitors of β1 integrin, MAPK, or phosphatidylinositol 3-kinase (P13K). MDA-MB-231 cells, which lack E-cadherin, were transfected with an E-cadherin cDNA. The extent of reversion was assessed by changes in morphology and polarity, growth in 3D rBM or soft agar, level of invasiveness, and tumor formation in nude mice. Results: All three cell lines showed partial reversion (MCF7 greatest and Hs578T the least) of tumorigenic properties treated with a single β1 integrin, MAPK, or P13K inhibitor. Combined inhibition of β1 integrin and either P13K or MAPK resulted in nearly complete phenotypic reversion (MDA-MB-231, MCF7) or in cell death (Hs578T). E-cadherin-transfected MDA-MB-231 cells showed partial reversion, but exposure of the transfectants to an inhibitor of β1 integrin, P13K, or MAPK led to nearly complete reversion. Conclusion: The 3D rBM assay can be used to identify signaling pathways that, when manipulated in concert, can lead to the restoration of morphologically normal breast structures or to death of the tumor cells, even highly metastatic cells. This approach may be useful to design therapeutic intervention strategies for aggressive breast cancers.",
author = "Fei Wang and Hansen, {Rhonda K.} and Radisky, {Derek C} and Toshiyuki Yoneda and Barcellos-Hoff, {Mary Helen} and Petersen, {Ole W.} and Turley, {Eva A.} and Bissell, {Mina J.}",
year = "2002",
month = "10",
day = "2",
language = "English (US)",
volume = "94",
pages = "1494--1503",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "19",

}

TY - JOUR

T1 - Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts

AU - Wang, Fei

AU - Hansen, Rhonda K.

AU - Radisky, Derek C

AU - Yoneda, Toshiyuki

AU - Barcellos-Hoff, Mary Helen

AU - Petersen, Ole W.

AU - Turley, Eva A.

AU - Bissell, Mina J.

PY - 2002/10/2

Y1 - 2002/10/2

N2 - Background: We previously used a three-dimensional (3D) reconstituted basement membrane (rBM) assay to demonstrate that tumorigenic HMT-3522 T4-2 human breast cells can be induced to form morphologically normal structures ("reversion") by treatment with inhibitors of β1 integrin, the epidermal growth factor receptor (EGFR), or mitogen-activated protein kinase (MAPK). We have now used this assay to identify reversion and/or death requirements of several more aggressive human breast cancer cell lines. Methods: Breast tumor cell lines MCF7, Hs578T, and MDA-MB-231 were cultured in 3D rBM and treated with inhibitors of β1 integrin, MAPK, or phosphatidylinositol 3-kinase (P13K). MDA-MB-231 cells, which lack E-cadherin, were transfected with an E-cadherin cDNA. The extent of reversion was assessed by changes in morphology and polarity, growth in 3D rBM or soft agar, level of invasiveness, and tumor formation in nude mice. Results: All three cell lines showed partial reversion (MCF7 greatest and Hs578T the least) of tumorigenic properties treated with a single β1 integrin, MAPK, or P13K inhibitor. Combined inhibition of β1 integrin and either P13K or MAPK resulted in nearly complete phenotypic reversion (MDA-MB-231, MCF7) or in cell death (Hs578T). E-cadherin-transfected MDA-MB-231 cells showed partial reversion, but exposure of the transfectants to an inhibitor of β1 integrin, P13K, or MAPK led to nearly complete reversion. Conclusion: The 3D rBM assay can be used to identify signaling pathways that, when manipulated in concert, can lead to the restoration of morphologically normal breast structures or to death of the tumor cells, even highly metastatic cells. This approach may be useful to design therapeutic intervention strategies for aggressive breast cancers.

AB - Background: We previously used a three-dimensional (3D) reconstituted basement membrane (rBM) assay to demonstrate that tumorigenic HMT-3522 T4-2 human breast cells can be induced to form morphologically normal structures ("reversion") by treatment with inhibitors of β1 integrin, the epidermal growth factor receptor (EGFR), or mitogen-activated protein kinase (MAPK). We have now used this assay to identify reversion and/or death requirements of several more aggressive human breast cancer cell lines. Methods: Breast tumor cell lines MCF7, Hs578T, and MDA-MB-231 were cultured in 3D rBM and treated with inhibitors of β1 integrin, MAPK, or phosphatidylinositol 3-kinase (P13K). MDA-MB-231 cells, which lack E-cadherin, were transfected with an E-cadherin cDNA. The extent of reversion was assessed by changes in morphology and polarity, growth in 3D rBM or soft agar, level of invasiveness, and tumor formation in nude mice. Results: All three cell lines showed partial reversion (MCF7 greatest and Hs578T the least) of tumorigenic properties treated with a single β1 integrin, MAPK, or P13K inhibitor. Combined inhibition of β1 integrin and either P13K or MAPK resulted in nearly complete phenotypic reversion (MDA-MB-231, MCF7) or in cell death (Hs578T). E-cadherin-transfected MDA-MB-231 cells showed partial reversion, but exposure of the transfectants to an inhibitor of β1 integrin, P13K, or MAPK led to nearly complete reversion. Conclusion: The 3D rBM assay can be used to identify signaling pathways that, when manipulated in concert, can lead to the restoration of morphologically normal breast structures or to death of the tumor cells, even highly metastatic cells. This approach may be useful to design therapeutic intervention strategies for aggressive breast cancers.

UR - http://www.scopus.com/inward/record.url?scp=0037009820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037009820&partnerID=8YFLogxK

M3 - Article

C2 - 12359858

AN - SCOPUS:0037009820

VL - 94

SP - 1494

EP - 1503

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 19

ER -